Meyka Pro banner
Ocugen, Inc.

Ocugen, Inc. Fundamental Analysis (NASDAQ: OCGN)

OCGNNASDAQ
HealthcareBiotechnology
$1.39
$0.00(0.00%)
U.S. Market opens in 46h 54m

Ocugen, Inc. Fundamental Analysis (NASDAQ: OCGN)

Ocugen, Inc. (NASDAQ: OCGN) shows moderate financial fundamentals with a PE ratio of -5.47, profit margin of -17.86%, and ROE of 16.88%. The company generates $0.0B in annual revenue with moderate year-over-year growth of 8.83%.

Key Strengths

Cash Position21.25%
PEG Ratio0.25

Areas of Concern

Operating Margin-15.04%
Current Ratio0.80
We analyze OCGN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1237.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1237.1/100

We analyze OCGN's fundamental strength across five key dimensions:

Efficiency Score

Weak

OCGN struggles to generate sufficient returns from assets.

ROA > 10%
-65.87%

Valuation Score

Excellent

OCGN trades at attractive valuation levels.

PE < 25
-5.47
PEG Ratio < 2
0.25

Growth Score

Moderate

OCGN shows steady but slowing expansion.

Revenue Growth > 5%
8.83%
EPS Growth > 10%
-15.00%

Financial Health Score

Moderate

OCGN shows balanced financial health with some risks.

Debt/Equity < 1
-5.31
Current Ratio > 1
0.80

Profitability Score

Weak

OCGN struggles to sustain strong margins.

ROE > 15%
16.88%
Net Margin ≥ 15%
-17.86%
Positive Free Cash Flow
No

Key Financial Metrics

Is OCGN Expensive or Cheap?

P/E Ratio

OCGN trades at -5.47 times earnings. This suggests potential undervaluation.

-5.47

PEG Ratio

When adjusting for growth, OCGN's PEG of 0.25 indicates potential undervaluation.

0.25

Price to Book

The market values Ocugen, Inc. at -28.23 times its book value. This may indicate undervaluation.

-28.23

EV/EBITDA

Enterprise value stands at -6.85 times EBITDA. This is generally considered low.

-6.85

How Well Does OCGN Make Money?

Net Profit Margin

For every $100 in sales, Ocugen, Inc. keeps $-17.86 as profit after all expenses.

-17.86%

Operating Margin

Core operations generate -15.04 in profit for every $100 in revenue, before interest and taxes.

-15.04%

ROE

Management delivers $16.88 in profit for every $100 of shareholder equity.

16.88%

ROA

Ocugen, Inc. generates $-65.87 in profit for every $100 in assets, demonstrating efficient asset deployment.

-65.87%

Following the Money - Real Cash Generation

Operating Cash Flow

Ocugen, Inc. generates limited operating cash flow of $-61.30M, signaling weaker underlying cash strength.

$-61.30M

Free Cash Flow

Ocugen, Inc. generates weak or negative free cash flow of $-61.46M, restricting financial flexibility.

$-61.46M

FCF Per Share

Each share generates $-0.18 in free cash annually.

$-0.18

FCF Yield

OCGN converts -13.07% of its market value into free cash.

-13.07%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.47

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.25

vs 25 benchmark

P/B Ratio

Price to book value ratio

-28.23

vs 25 benchmark

P/S Ratio

Price to sales ratio

102.18

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-5.31

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.80

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

16.88

vs 25 benchmark

ROA

Return on assets percentage

-0.66

vs 25 benchmark

ROCE

Return on capital employed

7.76

vs 25 benchmark

How OCGN Stacks Against Its Sector Peers

MetricOCGN ValueSector AveragePerformance
P/E Ratio-5.4730.97 Better (Cheaper)
ROE1688.22%515.00% Excellent
Net Margin-1786.27%30197.00% Weak
Debt/Equity-5.310.53 Strong (Low Leverage)
Current Ratio0.805.71 Weak Liquidity
ROA-65.87%-16.00% (disorted) Weak

OCGN outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Ocugen, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

3737.37%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-16.25%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-44.81%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ